Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Down 6.1% in November

Structure Therapeutics Inc. (NASDAQ:GPCR) was the target of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 10,550,000 shares, a drop of 6.1% from the November 15th total of 11,230,000 shares. Based on an average daily volume of 788,200 shares, the days-to-cover ratio is presently 13.4 days. Approximately 19.5% of the company’s shares are short sold.

Institutional Investors Weigh In On Structure Therapeutics

A number of large investors have recently made changes to their positions in the stock. Sandia Investment Management LP purchased a new stake in Structure Therapeutics during the 2nd quarter valued at about $39,000. Assetmark Inc. raised its holdings in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the last quarter. Quarry LP acquired a new stake in Structure Therapeutics during the 2nd quarter worth about $79,000. Mirae Asset Global Investments Co. Ltd. grew its position in Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after purchasing an additional 1,420 shares during the period. Finally, Dearborn Partners LLC acquired a new position in shares of Structure Therapeutics in the 3rd quarter valued at about $202,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

GPCR stock traded down $0.23 during trading on Tuesday, reaching $30.77. The company had a trading volume of 158,083 shares, compared to its average volume of 782,784. Structure Therapeutics has a twelve month low of $26.61 and a twelve month high of $62.74. The company has a market cap of $1.76 billion, a price-to-earnings ratio of -41.89 and a beta of -3.41. The firm has a 50-day simple moving average of $36.13 and a 200-day simple moving average of $39.19.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Morgan Stanley began coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price target on the stock. HC Wainwright assumed coverage on shares of Structure Therapeutics in a research note on Wednesday, December 4th. They issued a “buy” rating and a $80.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $85.67.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.